8/17/2020 7:34:16 AM
Blackstone And Alnylam Close $150 Mln R&D Financing To Advance RNAi Therapeutics For Cardiovascular Disease
8/6/2020 8:09:44 AM
Alnylam Pharmaceuticals Inc. (ALNY) Has Raised Its FY20 Revenue Estimate To $280 - $300 Mln From $270 - $300 Mln
8/6/2020 8:04:25 AM
Alnylam Pharma Q2 Non-GAAP Loss/shr Narrows To $1.67 From $1.83 Prior Year
8/6/2020 7:34:49 AM
Alnylam Says Barry Greene, President, Decided To Leave Company At
Q3 End
8/3/2020 7:35:32 AM
Alnylam Pharma Submits CTA Application For ALN-HSD For The Treatment Of Nonalcoholic Steatohepatitis
6/30/2020 9:07:16 AM
Alnylam Presents New Data From Open-label Extension Period Of
ENVISION Phase 3 Study
5/26/2020 7:04:10 AM
Alnylam Says FDA Granted Priority Review Of Lumasiran NDA
5/6/2020 8:04:03 AM
Alnylam Pharma Q1 GAAP Loss Per Share $1.62; Non-GAAP Loss Per Share $1.52